Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

Glucagon‐like peptide‐1 (7‐36) amide (GLP‐1) is a 30‐residue peptide hormone released
from intestinal L cells following nutrient consumption. It potentiates the glucose‐induced …

GLP-1 (glucagon-like peptide-1) is an incretin released from intestinal L-cells in response to
food intake. Activation of the GLP-1 receptor potentiates the synthesis and release of insulin …

Class B G-protein-coupled receptors are a small family of 15 peptide-binding receptors. This
family includes at least six biologically attractive therapeutic targets for both peptide ligands …

The glucagon-like peptide-1 receptor (GLP-1R) belongs to Family B1 of the seven-
transmembrane G protein-coupled receptors, and its natural agonist ligand is the peptide …

The glucagon-like peptide-1 receptor (GLP-1R) has broad physiological roles and is a
validated target for treatment of metabolic disorders. Despite recent advances in GLP-1R …

G-protein-coupled receptors (GPCRs) represent the largest constellation of validated drug
targets. Crystal structures of class A GPCRs have facilitated major advances in …

Aim Earlier studies have shown that peptide glucagon‐like peptide‐1 receptor (GLP‐1R)
agonists with reduced β‐arrestin recruitment show enhanced anti‐hyperglycaemic efficacy …

Long-acting glucagon-like peptide-1 (GLP-1) analogues marketed for type 2 diabetes (T2D)
treatment have been showing positive and protective effects in several different tissues …